Imatinib-Induced Acquired Dermal Melanocytosis

Background: Imatinib, a tyrosine kinase inhibitor targeting bcr-abl, c-Kit, and PDGF receptors-alpha and beta, is commonly used to treat GI stromal tumors and hematologic malignancies. Hyperpigmentation is a known side-effect of imatinib, with intradermal hemosiderosis being the most common histologic finding. Case Presentation: We report a rare case of concurrent hypopigmentation and hyperpigmentation secondary to dermal melanocytosis following imatinib treatment in an African American patient with acute lymphoblastic leukemia. Conclusion: Early referral to dermatology in patients with similar findings is appropriate given the increased risk of melanoma conferred by heightened melanocyte proliferation.